What are the defects?
A recent retrospective analysis of pooled clinical trial data showed that the incidence of cardiovascular ischemic events in patients taking Zelmac was higher than in those taking placebo.
What are the hazards?
Potentially life-threatening or a serious risk to health (Class I).
What should consumers do?
Letters were dispatched to doctors, pharmacies, and hospital pharmacies commencing 4 April 2007.
Novartis Pharmaceuticals Pty Ltd
Where the product was sold